Related Experiment Video

Updated: Oct 13, 2026

Enhancing the Engraftment of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes via a Transient Inhibition of Rho Kinase Activity
08:00

Enhancing the Engraftment of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes via a Transient Inhibition of Rho Kinase Activity

Published on: July 10, 2019

UCN-01, a protein kinase C inhibitor, inhibits endothelial cell proliferation and angiogenic hypoxic response

E A Kruger1, M V Blagosklonny, S C Dixon

  • 1Medicine Branch, Division of Clinical Sciences, National Cancer Institute, NIH, Bethesda, MD., USA.

Invasion & Metastasis
|January 21, 2000
PubMed

Insights

UCN-01, a protein kinase C (PKC) inhibitor, shows anti-angiogenesis effects by inhibiting endothelial cell proliferation and blocking cancer cell responses to hypoxia. This suggests UCN-01 may be a novel cancer therapy by preventing tumor vascularization.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Tumor growth and metastasis depend on angiogenesis, the formation of new blood vessels.
  • Inhibiting angiogenesis is a key strategy in cancer therapy.
  • UCN-01 is a protein kinase C (PKC) inhibitor with known anti-cancer properties.

Purpose of the Study:

  • To investigate the anti-angiogenic effects of UCN-01.
  • To determine if UCN-01 affects endothelial cell proliferation and the hypoxia-inducible factor (HIF-1) pathway.
  • To evaluate UCN-01's potential as an anti-neovascularization agent in cancer treatment.

Main Methods:

  • Assessing the effect of UCN-01 on human endothelial cell proliferation in vitro.
  • Evaluating UCN-01's impact on microvessel outgrowth from rat aortic ring explants.
  • Analyzing UCN-01's influence on HIF-1-responsive promoter constructs in a prostate cancer cell line under hypoxic conditions.

Main Results:

  • UCN-01 inhibited human endothelial cell proliferation at concentrations lower than those affecting cancer cell growth.
  • UCN-01 prevented microvessel outgrowth in rat aortic ring cultures at concentrations as low as 32 nM.
  • UCN-01 abrogated hypoxia-mediated transactivation of HIF-1-responsive promoters in prostate cancer cells.

Conclusions:

  • UCN-01 exhibits anti-neovascularization effects by inhibiting endothelial cell proliferation.
  • UCN-01 blocks the cancer cell response to hypoxia, thereby inhibiting tumor angiogenesis.
  • UCN-01 demonstrates potential as a therapeutic agent for cancer by targeting key steps in vessel formation at clinically relevant concentrations.

More Related Videos

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

Modified In Vivo Matrix Gel Plug Assay for Angiogenesis Studies09:03

Modified In Vivo Matrix Gel Plug Assay for Angiogenesis Studies

Published on: June 30, 2023

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...